CC-10004 For The Treatment Of Vulvodynia

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Vulvodynia
Interventions
DRUG

CC-10004

CC-10004 20 mg. twice a day for 12 weeks

Trial Locations (1)

48073

William Beaumont Hospital, Royal Oak

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Kenneth Peters, MD

OTHER